DIAGNOSIS AND RISK STRATIFICATION OF CARDIAC INSUFFICIENCY BY MEANS OF NATRIURETIC PEPTIDES FOR NYHA I PATIENTS

摘要

In-vitro diagnosis or risk classification or outcome prognosis of heart failure, involves utilizing determination of the marker proatrial natriuretic peptide (proANP) or N-terminal fragment of proatrial natriuretic peptide (NT-proANP) or fragments or part of peptide, parallel to a determination of the marker pro-brain natriuretic peptide (proBNP), N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) or brain natriuretic peptide (BNP), at a patient to be examined.